All conditions

Bladder Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1560
Trials on record
308
Recruiting now
20
Australian sites
32
Phase 3 trials
7
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Bladder Cancer →

Get alerts when Bladder Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Bladder Cancer

Bladder cancer is a condition where abnormal cells grow in the lining of the bladder, which is the hollow organ in your lower abdomen that stores urine. These cells can multiply in an uncontrolled way and, depending on how deeply they have grown into the bladder wall, doctors will describe the cancer as either "non-muscle-invasive" (where the cancer is still close to the surface) or "muscle-invasive" (where it has grown deeper into the bladder tissue). The most common type is called urothelial carcinoma. One of the most frequently noticed signs is blood in the urine, though this can have many causes, which is why a proper diagnosis from a medical team is so important.

In Australia, bladder cancer is one of the more commonly diagnosed cancers, with around 3,000 Australians diagnosed each year. It tends to affect older adults and is significantly more common in men than women, though women can and do receive this diagnosis too. Smoking is the single biggest known risk factor, and prolonged exposure to certain industrial chemicals has also been linked to an increased risk.

Treatment generally depends on the stage and type of cancer found. For cancers that have not grown deeply into the bladder wall, doctors often use a procedure called a TURBT (transurethral resection of bladder tumour) to remove the abnormal tissue, sometimes followed by medications placed directly into the bladder. For more advanced cases, options can include surgery to remove the bladder, radiation therapy, or chemotherapy, and these approaches are sometimes used in combination. Your medical team will explain what options are relevant to your specific situation, and it is completely reasonable to ask questions and take time to understand what each option involves.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Bladder Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Bladder Cancer

7 medicines listed on the PBS for Bladder Cancer. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 7 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Avelumab Bavencio urothelial cancer Locally advanced (Stage III) or metastatic (Stage IV) AU$1289.49 Streamlined authority
Enfortumab vedotin Padcev urothelial cancer Locally advanced (Stage III) or metastatic (Stage IV) AU$942.06 Streamlined authority
Pembrolizumab Keytruda urothelial cancer Locally advanced (Stage III) or metastatic (Stage IV) AU$3632.56 Streamlined authority
Mycobacterium bovis BCG Danish strain VesiCulture superficial urothelial carcinoma of the bladder Primary and relapsing AU$550 Restricted benefit
Mycobacterium bovis BCG Tice strain OncoTICE superficial urothelial carcinoma of the bladder Primary and relapsing AU$399.49 Restricted benefit
Durvalumab Imfinzi Urothelial carcinoma AU$860.99 Streamlined authority
Nivolumab Opdivo Urothelial carcinoma AU$1972.83 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Bladder Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Bladder Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Bladder Cancer by country. Australia is highlighted.

Showing the top 10 of 47 countries with trial sites.

Clinical trials for Bladder Cancer

Showing 313 of 313 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT04165317 · Pfizer Phase 3 · 14 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 2 December 2024
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +6 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of bladder cancer (called transitional cell carcinoma) that is considered high risk but has not spread into the muscle of the bladder wall, confirmed by a tissue sample (biopsy) - All visible tumour growths in the bladder have bee...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02387996 · Bristol-Myers Squibb Phase 2 · 11 countries Completed
Completed Phase 2 Est. completion 15 April 2016
🇦🇺 AU🇧🇪 BE🇨🇿 CZ🇫🇮 FI🇩🇪 DE🇮🇹 IT🇯🇵 JP🇵🇱 PL +3 more

Who might be able to join this trial: - You have bladder cancer or cancer of the urinary tract (such as the urethra, ureter, or kidney's drainage system) that has spread to other parts of the body or cannot be removed by surgery - Your cancer can be measured on a CT or MRI scan - Your cancer has come back or gotten wor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03785925 · Nektar Therapeutics Phase 2 · 18 countries Completed
Completed Phase 2 Est. completion 9 February 2022
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇮 FI🇫🇷 FR🇩🇪 DE🇬🇷 GR +10 more

Who might be able to join this trial: - You are willing to give written consent to take part and follow the study's procedures - Your general health and ability to carry out daily activities meets a certain level (your doctor can assess this) - Your cancer can be measured on scans according to standard guidelines - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04564781 · Cedars-Sinai Medical Center Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 February 2030
🇦🇺 AU🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a specific type of bladder cancer (urothelial cell carcinoma) at an early stage (called Ta, CIS, or T1), confirmed by a tissue sample taken within the last 90 days - Any visible tumors in your bladder have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT04585750 · PMV Pharmaceuticals, Inc Phase 2 · 9 countries Recruiting
Recruiting Phase 2 Est. completion 15 August 2026
🇦🇺 AU🇫🇷 FR🇩🇪 DE🇮🇹 IT🇸🇬 SG🇰🇷 KR🇪🇸 ES🇬🇧 GB +1 more

**Who might be able to join this trial:** - Adults aged 18 or older, or teenagers aged 12–17 if a Safety Review Committee has given approval for that age group. - People who have a solid tumour (cancer that forms a mass) that has spread locally or to other parts of the body, and whose tumour has a specific genetic cha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04752722 · enGene, Inc. Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇰🇷 KR🇪🇸 ES🇹🇼 TW +2 more

**Who might be able to join this trial:** - You have early-stage bladder cancer (non-muscle-invasive) with a type called carcinoma in situ (CIS), with or without other small tumours, and your cancer has not responded well enough to BCG treatment (a common bladder cancer therapy). - You are not able to have, or have ch...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04879329 · Seagen, a wholly owned subsidiary of Pfizer Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 11 December 2026
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇱 CL🇮🇱 IL🇮🇹 IT🇯🇵 JP +4 more

Who might be able to join this trial: **All groups generally require:** - Having a confirmed diagnosis of advanced or spreading cancer of the urinary tract (such as the bladder, kidneys, ureters, or urethra) that cannot be removed by surgery - Having at least one area of cancer that can be measured on a scan - Being w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05080998 · Pacific Edge Limited Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with urothelial carcinoma (a type of bladder cancer) or had it return within the last 3 years, and are currently being monitored at low, intermediate, or high risk of recurrence. - People who are willing and able to attend 4 study visits and pro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05483868 · Aura Biosciences Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC), confirmed by a tissue sample taken during a procedure or biopsy, with specific requirements depending on which group (cohort) of the trial applies to them (confirm with...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05614739 · Eli Lilly and Company Phase 1 · 14 countries Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇯🇵 JP +6 more

**Who might be able to join this trial:** - People who have a solid tumour cancer with a specific change (called an FGFR3 pathway alteration) found through testing of a tumour or blood sample, where that change is considered meaningful for treatment - Depending on which group (cohort) a person is assigned to, eligibil...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05706129 · ITM Oncologics GmbH Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇦🇺 AU🇫🇷 FR

Who might be able to join this trial: - People who have given written, dated, and signed consent before any study procedures begin. - People with a confirmed diagnosis of certain advanced or spread cancers that cannot be removed by surgery, depending on which part of the trial they are entering (see below). - For kidn...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06172478 · Daiichi Sankyo Phase 2 · 16 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇹 IT +8 more

**Who might be able to join this trial:** - People aged 18 or older who are willing and able to sign a consent form before any study procedures begin - People with advanced cancer that cannot be removed by surgery or cured by radiation, and whose cancer falls into one of the following types: - People with skin (cutane...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06351904 · Ractigen Therapeutics. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 August 2028
🇦🇺 AU

**Who might be able to join this trial:** - People aged 18 or older - People who are able to understand the study and have signed a consent form - People who have been diagnosed with high-grade non-muscle-invasive bladder cancer (a specific type of bladder cancer confirmed by laboratory testing, graded as grade 2 or g...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06465069 · Eli Lilly and Company Phase 1 · 8 countries Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇦🇺 AU🇨🇳 CN🇫🇷 FR🇯🇵 JP🇰🇷 KR🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have one of the following solid tumour cancers, depending on the group (cohort) they would be placed in: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, head an...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06833073 · Merck Sharp & Dohme LLC Phase 2 · 19 countries Recruiting
Recruiting Phase 2 Est. completion 3 September 2031
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇴 CO🇩🇰 DK🇫🇷 FR +11 more

**Who might be able to join this trial:** - Your most recent bladder surgery (called TURBT) was done within the past 12 weeks, and results confirmed a specific type of high-risk bladder cancer that has not spread into the muscle wall - **Group A:** You have high-risk, non-muscle-invasive bladder cancer (specific stage...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06960577 · AstraZeneca Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 31 October 2028
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇫🇷 FR🇮🇹 IT🇳🇱 NL🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with bladder cancer at a specific stage (T2 to T4a, or T1 with some lymph node involvement, but not spread to distant parts of the body), and your cancer is a type called transitional or mixed transitional cell cancer (confirm with trial site) - You ar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06995677 · Tyra Biosciences, Inc Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇦🇺 AU🇮🇹 IT🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 and over who are willing and able to follow all study procedures - People who can understand the study information and provide written consent - People with a confirmed diagnosis of low-grade, non-muscle-invasive bladder cancer (a type of bladder cancer that h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07106762 · Bristol-Myers Squibb Phase 3 · 22 countries Recruiting
Recruiting Phase 3 Est. completion 26 January 2029
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ +14 more

Who might be able to join this trial: - You have been diagnosed with advanced bladder or urinary tract cancer that has been confirmed by a lab test (biopsy). - You are able to receive a type of chemotherapy that contains platinum (such as cisplatin or carboplatin). - You have previously been treated with a type of immu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07186842 · BioNTech SE Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2030
🇦🇺 AU🇩🇪 DE🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are able to carry out normal daily activities with little or no limitation (based on a standard performance scale used by doctors) - Your cancer can be measured on scans using standard medical guidelines - Your doctor believes you are expected to live for at least 3 mont...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07218380 · Eli Lilly and Company Phase 3 · 19 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2029
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE +11 more

**Who might be able to join this trial:** - You have been diagnosed with bladder or urinary tract cancer (urothelial cancer) that cannot be removed by surgery and has either spread to nearby tissues or to other parts of the body, confirmed by a tissue biopsy. Mixed cancer types may be eligible as long as urothelial can...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07419295 · Merck Sharp & Dohme LLC Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 27 July 2029
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇬🇷 GR +7 more

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced or metastatic bladder/urinary tract cancer (urothelial cancer) confirmed by a tissue sample, where the cancer cannot be removed by surgery or cured with radiation - People whose cancer can be measured on scans according to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07421700 · Pfizer Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 6 December 2027
🇦🇺 AU🇨🇳 CN🇯🇵 JP Puerto Rico🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older at the time of screening. - You must have been diagnosed with advanced or spreading bladder/urinary tract cancer that has been confirmed by a tissue sample (biopsy). - Your cancer must be measurable on scans using standard medical guidelines. - Y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07660055 · Novartis Pharmaceuticals Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 24 May 2032
🇦🇺 AU🇨🇦 CA🇯🇵 JP

**Who might be able to join this trial:** - Adults aged 18 or older - People with a confirmed diagnosis of certain advanced cancers that have continued to grow or spread after standard treatments, and where no other standard treatment with proven benefit is considered appropriate by the treating doctor - People with a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02554812 · Pfizer Phase 2 · 8 countries Terminated
Terminated Phase 2 Est. completion 23 March 2023
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇯🇵 JP🇵🇱 PL🇹🇼 TW🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with an advanced or spreading solid tumour, confirmed by a tissue or cell sample. - People who have at least one tumour that can be measured on a scan (using standard measurement guidelines) and has not previously been treated with radiation. -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00026884 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cancer confirmed by a biopsy (tissue sample) - You are suspected of having cancer, even if it has not been confirmed yet - You have or are suspected of having an inherited cancer condition affecting the urinary or reproductive system - You are 2 years...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02379429 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: **For people with urothelial (bladder/urinary tract) cancer:** - Adults aged 18 or older who have been diagnosed with, or are suspected to have, urothelial cancer and need some form of medical procedure as part of their diagnosis, treatment, or follow-up care. - People who are rea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02660645 · Photocure Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - Adults who are over 18 years old - People who have had a prior camera examination of the bladder (cystoscopy) that showed suspected or confirmed bladder cancer that has not spread into the bladder muscle Who may not be able to join: - People who have a condition called porphyria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03108196 · Zhujiang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with bladder cancer in situ (an early stage where cancer cells are present but haven't grown into deeper layers), including specific types called CIS or T1G3 tumours, or muscle-invasive bladder cancer at certain stages (T2/T3 with limited spread). - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03185468 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced or metastatic urothelial bladder cancer (a cancer affecting the lining of the urinary tract, including the kidney pelvis, ureters, bladder, or urethra), confirmed by a tissue or cell sample - People who are able to provide...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03193515 · Cedars-Sinai Medical Center Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with bladder cancer (either the type that has not grown into the muscle wall, or the type that has grown into the muscle wall but was treated without removing the bladder, or has not yet been treated), with the di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03193541 · Cedars-Sinai Medical Center Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 February 2029
🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have had microscopic blood in their urine (too small to see with the naked eye) recorded or reported within the last 3 months before joining the study - People who are willing and able to sign a written consent form **Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03193970 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2034
🇺🇸 US

**Who might be able to join this trial:** - People with bladder cancer who are scheduled to have their bladder surgically removed (a major operation called radical cystectomy) at MD Anderson Cancer Center or one of its partner hospitals. **Who may not be able to join:** - No specific exclusion criteria have been liste...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03216525 · Brigham and Women's Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2023
🇺🇸 US

**Who might be able to join this trial:** - You are scheduled to have your bladder fully removed and a new way of passing urine created, either through open surgery or using a robot-assisted approach. - You are between 18 and 85 years old. - Your overall health has been assessed by an anesthesiologist and rated as suit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03379909 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2024
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged over 18 years - People who have a first-time or returning suspected low-grade bladder cancer (called Ta or T1, Grade 1 or 2 urothelial carcinoma) with no suspicion of a type called carcinoma in situ - People who have between 1 and 5 bladder tumours - People who h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03413982 · University of Kansas Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇺🇸 US

Who might be able to join this trial: - You may be eligible if you have been diagnosed with bladder cancer or your doctor suspects you may have bladder cancer. - You can still take part in other research studies at the same time as this trial. Who may not be able to join: - You would not be eligible if you do not have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03844256 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2024
🇳🇱 NL

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form for the trial. - People who are 18 years of age or older at the time of signing the consent form. - People who wish to keep their bladder (rather than have it removed), or who have been assessed as not suitable f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03945162 · Theralase® Technologies Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form for the study. - People who are older than 18 years of age at the time of signing the consent form. - People who have been diagnosed with a specific type of non-muscle-invasive bladder cancer (called carcinoma in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03973671 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇧🇪 BE

Who might be able to join this trial: - People aged between 18 and 90 years old - People of any sex (male or female) - People who agree to allow their medical and tissue data to be collected for research - People who are scheduled to have a surgical procedure called TURBT to remove or examine a bladder tumour - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04106115 · University College, London Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 March 2027
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with high-risk bladder cancer that has not grown into the muscle wall of the bladder, confirmed by a tissue sample. - People who have a stored tissue sample available that was taken within the last 6 months before treatment is due to start. - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04197414 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with a urological cancer, specifically prostate cancer, kidney cancer, bladder cancer, or ureter cancer - People who had surgery for one of these cancers at Severance Hospital, Sinchon, between December 2019 and November 2029 - People who agree to a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04235764 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You need to be having surgery to remove your bladder at the NIH Clinical Center (this could be due to bladder cancer or another serious bladder condition where a surgeon has recommended removal) - You can be male or female - You can be any age, whether you are under or over...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04235777 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a metastatic genitourinary cancer (a cancer affecting the urinary or reproductive system, but not prostate cancer), confirmed by a laboratory test on a tissue or cell sample. - People whose cancer has spread or grown, shown by a scan taken...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04368702 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2029
🇺🇸 US

Who might be able to join this trial: - The person has a cancer diagnosis that has been confirmed by laboratory testing of cells or tissue, and the cancer requires radiation treatment. - The person is 18 years of age or older. - The person is well enough to carry out daily activities with minimal limitations (based on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04369560 · Jodi Maranchie Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 90 years old - People who are able to understand and are willing to sign a written consent form - People who have a papillary growth in their bladder found during a camera examination (cystoscopy) and are scheduled for a surgical procedure to remove it, OR p...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04389632 · Seagen, a wholly owned subsidiary of Pfizer Phase 1 · 7 countries Recruiting
Recruiting Phase 1 Est. completion 16 June 2027
🇫🇷 FR🇰🇷 KR🇪🇸 ES🇨🇭 CH🇹🇼 TW🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer that has spread or cannot be surgically removed, confirmed by a lab test — eligible cancer types include non-small cell lung cancer, head and neck squamous cell cancer, HER2-negative breast cancer, esophageal squamous ce...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04428554 · Institut Claudius Regaud Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2031
🇫🇷 FR

**Who might be able to join this trial:** - You must be 18 years of age or older - You must be well enough to carry out basic daily activities with only minor limitations (your doctor can assess this using a standard scale) - You must have bladder cancer of a specific type called urothelial cancer, confirmed by a tiss...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04442724 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with bladder cancer (a type called urothelial carcinoma) confirmed by a tissue or cell sample. If the cancer is a mixed type, the main type must be the traditional urothelial (transitional cell) pattern. - People whose bladder cancer has been s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04503577 · Prospective Bladder Cancer Infrastructure Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2040
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with bladder cancer - People whose bladder cancer is at any stage except stage Ta (a very early, non-invasive stage) - People who are 18 years of age or older - People who are able and willing to provide written consent to participate Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04532606 · Peking University First Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 50 years or older and under 90 years old - People who have been diagnosed before surgery with a type of bladder cancer that has not grown into the muscle wall (known as non-muscle-invasive bladder cancer, stages Ta to T1) - People who are scheduled to have a proce...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04574960 · University Health Network, Toronto Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have been newly diagnosed with a specific type of kidney/urinary tract cancer (high-grade urothelial carcinoma) that has been confirmed by a scan, urine test, or biopsy, and has not spread to lymph nodes or other parts of the body - You are 18 years of age or older - You...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04724928 · University Hospital, Ghent Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇧🇪 BE

**Who might be able to join this trial:** - People who have been diagnosed with muscle-invasive bladder cancer (a cancer that has grown into the muscle wall of the bladder), confirmed by a tissue sample from a surgical procedure or by scans showing the cancer has reached a certain stage - People whose bladder cancer h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04861584 · Zhujiang Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old at the time of signing the consent form, regardless of gender - You are generally well enough to carry out daily activities with little or no limitation, and doctors expect you to live for more than 6 months - Tests have confirmed you have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04878029 · Emory University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 13 November 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with urothelial carcinoma (a type of bladder or urinary tract cancer), confirmed by a tissue sample. Mixed cell types are allowed as long as urothelial carcinoma is present. - People whose cancer has spread to other parts of the body (metastatic) or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04900558 · University of Florence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2031
🇮🇹 IT

Who might be able to join this trial: - You are 18 years old or older - You are scheduled to have surgery to completely remove your bladder (called a radical cystectomy) - You are willing to give your consent to take part in the study Who may not be able to join: - You do not wish to take part in the trial - You decid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04934540 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Hong Kong

Who might be able to join this trial: - You must be an adult aged 18 or older and willing to give your consent to take part - You must have a bladder tumour and be scheduled to have it removed using a procedure called transurethral en bloc resection (a surgical technique to remove the tumour through the urethra) Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04947059 · University of Thessaly Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2025
🇬🇷 GR

**Who might be able to join this trial:** - You have a bladder tumor, either newly diagnosed or one that has come back after previous treatment - Your surgery involves a standard type of bladder tumor removal procedure (using either bipolar or monopolar equipment) - Your kidney function blood test result is below a ce...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04970472 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 July 2026
🇫🇷 FR

Who might be able to join this trial: - People who are over 18 years old - People who have been diagnosed with, or are suspected to have, a type of cancer called urothelial carcinoma (a cancer that affects the lining of the bladder or urinary tract) - People who are willing to give their consent to take part in this st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04979156 · University of Kansas Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have a papillary bladder tumor (a specific type of bladder growth) that has been seen during a camera examination of the bladder (called a cystoscopy) and you are scheduled to have it surgically removed - Your bladder tumor is newly diagnose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04993859 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 July 2026
🇺🇸 US

**Who might be able to join this trial:** - The child must be between 5 and 13 years old - The child must have a history of cancer - The child must have been treated with a chemotherapy regimen that included vincristine (VCR) and/or doxorubicin (DOX) - The child must have finished chemotherapy at least one year before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05000294 · University of Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have already received at least one systemic (whole-body) treatment for advanced, inoperable, or metastatic cancer — or whose treating doctor considers there are no standard treatments that would provide meaningful benefit, or who cannot tolerate or have declined s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05002556 · Association Francaise d'Urologie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2034
🇫🇷 FR

Who might be able to join this trial: - People who are being monitored for a type of bladder tumour that has not grown into the bladder muscle, and who had a urine-based biomarker test before their surgical removal or diagnosis of a returning tumour - People who are 18 years of age or older - People who are enrolled in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05037279 · Verity Pharmaceuticals Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2029
🇨🇦 CA

**Who might be able to join this trial:** - People of any gender, aged 18 or older. - People diagnosed within the last 45 days with a specific type of early-stage bladder cancer (non-muscle-invasive bladder cancer, or NMIBC) that is low or high grade, confirmed by a pathologist and completely removed during surgery. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05067101 · Zhujiang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adult males aged 20 years or older (healthy volunteers are not accepted — participants must have a bladder condition) - People diagnosed with certain types of bladder cancer, including carcinoma in situ, high-grade early-stage bladder cancer (T1G3), or muscle-invasive bladder...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05072600 · Peking University First Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 7 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older who have given written consent to participate. - People diagnosed with bladder cancer (urothelial carcinoma making up more than 50% of the tumour) that has been staged as cT2-4N0M0 according to standard medical staging guidelines (confirm with trial s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05123625 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have not had a diagnostic bladder tumour removal procedure (TURBT) but whose biopsy or camera examination of the bladder suggests high-grade cancer, cancer in the lining of the bladder (CIS), multiple tumours, or a tumour larger than 3 cm — with specific scan scor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05126472 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** **For Cohorts A and B (non-muscle-invasive bladder cancer):** - People who have high-grade bladder cancer (that has not grown into the bladder muscle) of a type called urothelial carcinoma, which has not responded to a full course of BCG treatment (a type of bladder cancer imm...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05153694 · Ludwig-Maximilians - University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇩🇪 DE

"Who might be able to join this trial: - People who have a condition that requires their urinary bladder to be surgically removed. Who may not be able to join: - People who do not wish to take part in the trial. Important: Always verify eligibility with the trial site directly before applying."

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05203913 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with bladder cancer that is mainly a type called urothelial carcinoma (certain mixed cell types are allowed, but not small cell type) - People whose cancer is at a stage classified as T2–T3, with no spread to lymph nod...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05204108 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2021
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with bladder cancer that was confirmed through a tissue or cell sample (such as a biopsy) - You have not had any surgery, chemotherapy, immunotherapy, or other cancer treatments before the special ultrasound scan (called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05204186 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇫🇷 FR

"Who might be able to join this trial: - Adults aged 18 years or older - People who have had their bladder surgically removed as treatment for bladder cancer Who may not be able to join: - People whose CT or MRI scans show that the cancer has spread to other parts of the body Important: Always verify eligibility with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05232136 · Binhui Biopharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (inclusive), of any gender - Your bladder cancer has not invaded the muscle layer, and is classified as high grade at stage Ta, T1, or Tis - You have already tried a first-line bladder wash (instillation) treatment that did not work, and y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05239624 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with muscle-invasive bladder cancer (a type of cancer that can also affect the renal pelvis, ureter, or urethra), confirmed by laboratory testing of tissue samples - People whose cancer has been assessed as clinical stage T2–T4...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05264337 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇸🇪 SE

Who might be able to join this trial: - People who are having urologic (urinary system) surgery that includes the removal and examination of nearby lymph nodes. Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site). Important: Always verify eligibility...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05296564 · Hadassah Medical Organization Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇮🇱 IL

**Who might be able to join this trial:** - Your cancer has been confirmed through a tissue or cell sample (biopsy or lab test). - Your cancer has spread to other parts of the body or cannot be removed, and it cannot be cured with current treatments; any previously treated tumors must show signs of growth to be counte...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05312671 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed through a tissue sample (biopsy) with a specific type of bladder cancer that includes small cell or high-grade neuroendocrine features, with the cancer confined to the bladder and nearby lymph nodes (not spread to distant parts of the body). - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05316155 · Janssen Research & Development, LLC Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 30 March 2028
🇨🇦 CA🇩🇪 DE🇮🇱 IL🇯🇵 JP🇳🇱 NL🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** **For Parts 1–3:** - People diagnosed with bladder cancer that has grown into the muscle wall, or bladder cancer that has come back and has not grown into the muscle wall - For certain groups in the trial: People whose tumor has a specific genetic change (called an FGFR mutati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05327647 · CHU de Quebec-Universite Laval Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇦 CA

Who might be able to join this trial: - You are male and 18 years of age or older - You have been diagnosed with a type of bladder cancer (non-muscle invasive urothelial carcinoma) confirmed by a tissue sample test - Your urologist has recommended that you receive a course of BCG treatment directly into the bladder - Y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05337397 · Jørgen Bjerggaard Jensen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇩🇰 DK

Who might be able to join this trial: - Having at least one tumour that is larger than 1 cm in diameter - Having a papillary or non-solid type of bladder tumour - Having a history of low-grade, non-muscle-invasive bladder cancer (an early-stage form of bladder cancer that has not spread into the bladder muscle) - Being...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05397262 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2098
🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with bladder cancer confirmed through laboratory testing of tissue samples - People whose cancer has not spread to distant parts of the body (M0 stage) - People who are reasonably active and able to care for thems...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05410730 · Shanghai Hengrui Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and can sign a consent form after being told about the study - You are 18 years old or older (any gender) - You are reasonably active and able to care for yourself, with only limited restrictions on daily activities (confirm with tria...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05415631 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have a single suspected bladder tumor (new or returning) that is 3 cm or smaller in size - You have multiple suspected bladder tumors (new or returning), with no more than 5 tumors, each being 3 cm or smaller in size **Who may not be able to join:** - You have more than...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05453682 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with bladder cancer confirmed by a tissue sample (biopsy) - People whose cancer has grown into the muscle wall of the bladder (a stage known as pT2 or higher) - People whose scans (CT or MRI) show no cancer spread to the lymph nodes in the pelv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05519241 · VA Office of Research and Development Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with bladder carcinoma in situ (a type of early-stage bladder cancer confined to the inner lining) confirmed by tissue testing, with or without a T1 tumour (one that has grown slightly deeper but not into the muscle wall), where the biopsy was...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05521698 · University of Wisconsin, Madison Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - Biological males aged 18 or older - People whose bladder cancer has been identified as possibly not having grown into the bladder muscle (non-muscle invasive), based on a scope procedure or imaging reviewed by a qualified urologist - People who have had a CT or MRI scan of t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05558111 · Zhujiang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are right-handed - People who are at least 3 months past their surgery - People who have no medical reasons preventing them from having an fMRI scan - People who are willing to sign a consent form agreeing to take part **Who may not be able to join:** - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05562791 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** *For the Bladder Cancer (Urothelial Carcinoma) group:* - You have been diagnosed with bladder or urinary tract cancer that has spread beyond the pelvis to areas such as the lungs, liver, bones, or other tissues, confirmed by a tissue biopsy - You have at least one area of canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05592626 · Marengo Therapeutics, Inc. Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇦 CA🇫🇷 FR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have a solid tumor cancer that cannot be removed by surgery, has spread, or is at an advanced stage, and standard treatments are no longer working, don't exist, or have caused intolerable side effects — and you have had no more than three previous treatment regimens for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05621837 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with certain advanced or spreading cancers, confirmed by laboratory testing of tissue — these cancers include melanoma, breast cancer that no longer responds to hormone treatment, kidney cancer, bladder cancer, head and neck cancer, or non-small cel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05646485 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - You are 50 years old or older - You have a smoking history of at least 15 pack-years (for example, smoking one pack a day for 15 years, or two packs a day for 7.5 years) - You have worked for at least 15 years in an occupation with chemical or environmental exposures, such as a t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05649306 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - You are a woman who has been diagnosed with bladder cancer - You are willing to fill out surveys about your emotional wellbeing and sexual health Who may not be able to join: - You are not currently receiving treatment for bladder cancer or being actively monitored by doctors (f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05672615 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with bladder cancer that has not grown into the muscle wall of the bladder, confirmed by a laboratory test - People who are 18 years of age or older - People who are able to understand and willing to sign a written consent form agreeing to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05679557 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇩🇰 DK

Who might be able to join this trial: - People who have been diagnosed with muscle-invasive bladder cancer and are scheduled to have their bladder surgically removed. - People whose surgical plan includes a specific type of urinary diversion called an ileal conduit (where a small piece of bowel is used to redirect urin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05710848 · SURGE Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with high-grade non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread into the bladder muscle), specifically classified as Ta or T1, without a type called CIS — who have already complet...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05715684 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 December 2026
🇺🇸 US

Who might be able to join this trial: - People between 18 and 85 years of age who are scheduled for a full bladder removal surgery (cystectomy), performed either as open surgery or using a robotic approach. - People whose surgery will include a specific type of urinary diversion — either an ileal conduit (where urine d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05739968 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

Who might be able to join this trial: - People aged 20 years or older - People who have been newly diagnosed with a type of bladder cancer that has not grown into the muscle layer of the bladder, and whose bladder has not been surgically removed - People who are able to speak and communicate verbally with others - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05779631 · Radboud University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 years or older - People who have been clinically suspected of having muscle-invasive bladder cancer (a type of bladder cancer that has grown into the muscle wall of the bladder) - People whose cancer has not spread to the lymph nodes or other parts of the body - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05783271 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇬 EG

Who might be able to join this trial: - People of any age who are suspected of having bladder cancer, based on a doctor's assessment, tissue sample results, or medical imaging scans - Both males and females are eligible Who may not be able to join: - People whose kidneys are not working well, shown by abnormal kidney...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05790850 · University of Virginia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to sign and date a consent form agreeing to take part in the study - People who are willing to follow all study procedures and are available for the full duration of the study - People who are male or female, aged 18 years or older - People who a surge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05792033 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇦🇹 AT

**Who might be able to join this trial:** - You have been diagnosed with a specific early-stage bladder cancer (called primary T1 bladder cancer), confirmed by lab results from tissue samples. - Your diagnosis has been confirmed by a second surgical procedure to check the bladder (called a second-look TURB). - Scans an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05796375 · White River Junction Veterans Affairs Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older. - People who have a history of low-grade, early-stage bladder cancer (meaning the cancer has not grown into the bladder muscle), where the most recent tissue test showed one of the following: multiple small tumours that are low grade; a si...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05825950 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with intermediate or high-risk bladder cancer that has not grown into the deep muscle wall of the bladder (confirm with trial site for exact category details) - You have received treatment placed directly into the bladder (such as BCG, mitomycin C, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05833867 · Shilpa Gupta, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with muscle-invasive bladder cancer (a cancer that has grown into the muscle wall of the bladder), confirmed by a tissue or cell sample, at a stage where it has not spread to distant parts of the body (note: tumours with a small cell or neuroen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05879653 · Kyoto University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2025
🇯🇵 JP

Who might be able to join this trial: - Adults aged 18 or older who have recently received a first confirmed diagnosis of muscle-invasive bladder cancer (a cancer that has grown into the muscle wall of the bladder), with the cancer being mainly of a type called urothelial, confirmed by a surgical procedure within the p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05943379 · RemeGen Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have given voluntary written consent to take part in the study. - Adults aged 18 or older, of any gender. - People diagnosed with high-risk non-muscle-invasive bladder cancer (a type of bladder cancer that has not grown into the muscle wall) according to Chinese t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05951179 · Protara Therapeutics Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 1 October 2031
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇯🇵 JP🇺🇦 UA🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form - You have willingly given written consent to take part after the study has been fully explained to you - A specialist lab has confirmed you have a specific type of high-grade bladder condition called non-m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05962541 · University of Roma La Sapienza Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2028
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older (male or female) who have been referred because bladder cancer is suspected — either for the first time or as a return of a previous cancer — and whose doctor has recommended a surgical procedure to remove bladder tissue (called a TURBT). - People who...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05969964 · Mansoura University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇪🇬 EG

Who might be able to join this trial: - People who have had a surgical procedure called ERBT (a type of tumour removal) and whose final pathology results showed stage pT1 disease (an early stage of tumour growth) with clear margins, meaning no cancer cells were found at the edges of the removed tissue in any direction....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05982561 · Early is Good Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older - You must have been diagnosed with a new or returning non-muscle-invasive bladder cancer within the last 2 years, and be having a routine camera examination of the bladder (cystoscopy) as part of your normal care - You must be able to underst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06011954 · Astellas Pharma Korea, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇰🇷 KR

Who might be able to join this trial: - People who are receiving treatment with PADCEV Injection as directed by its officially approved local prescribing guidelines. Who may not be able to join: - People for whom PADCEV Injection is considered medically unsuitable or unsafe according to the officially approved local p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06026189 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇳🇱 NL

Who might be able to join this trial: - People whose urine has been tested under a microscope and shown to contain small amounts of blood (at least 3 red blood cells seen per high-powered microscope view), which is not visible to the naked eye - Men aged 40 years or older - Women aged 50 years or older Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06041503 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have locally advanced or spreading pure adenocarcinoma or pure squamous cell carcinoma of the urinary tract (including the kidney's collecting system, ureter, bladder, or urethra), or testicular germ cell tumors that ha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06091124 · RenJi Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are a man or woman aged 18 to 75 years old. - You are generally well enough to carry out daily activities, or have only mild limitations (confirm with trial site regarding how this is assessed). - You have been diagnosed through a tissue sample with a specific type of bl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06092450 · First Affiliated Hospital of Chongqing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with muscle-invasive bladder cancer, confirmed by a laboratory test, and have had surgery to remove the bladder (radical cystectomy). - You had a CT scan with contrast dye taken less than two weeks before your surgery. - Your full CT scan images and medica...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06101277 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 December 2033
🇺🇸 US

Who might be able to join this trial: - You must have one of these specific cancers, confirmed by lab testing: small bowel cancer (Cohort B), or pancreatic, ampullary, colorectal, or appendiceal cancer (Cohort C). - You must be at least 18 years old at the time you give your consent to join. - You must be willing to fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06108492 · Shanghai Hengrui Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing to take part voluntarily and sign a consent form agreeing to participate - You must be 18 years of age or older (any sex) - You must have previously had a tissue sample (biopsy) confirming you have intermediate or high-risk non-muscle-invasive bladder canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06109857 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have already had an in-clinic evaluation for blood in the urine, which included at least one of the following: a CT scan, an ultrasound, or a cystoscopy (a camera examination of the bladder) **Who may not be able to join:** - You have b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06116396 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 September 2025
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with a type of cancer affecting the urinary tract (such as the bladder or urinary passages) and have not yet received any treatment for it Who may not be able to join: - You have no history of any cancer or genetic (hereditary) conditions (confirm with tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06138561 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 65 years old or older (note: the trial limits the number of participants between ages 65 and 70 to 20% of the total group) - You have bladder cancer that cannot be removed by surgery or has spread to other parts of the body, and testing has confirmed it is a specific...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06167356 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 November 2063
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with bladder cancer that has not spread into the muscle layer of the bladder - People whose doctor has recommended surgery to remove the cancer using an internal camera and instruments (endoscopic resection)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06170177 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2063
🇮🇹 IT

Who might be able to join this trial: - People who have had a radical cystectomy (surgery to remove the bladder) - People who are older than 18 years of age - People who are able to read and sign a consent form agreeing to take part in the trial Who may not be able to join: - People who are under 18 years of age - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06173349 · University of California, Davis Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with non-muscle-invasive bladder cancer (a type of bladder cancer that has not grown deep into the bladder wall), confirmed by a surgical procedure to remove bladder tumours, done within 3 months of joining the trial - People whose bladder canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06184516 · University of Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are female and at least 18 years old - People who have been diagnosed with urothelial carcinoma (a type of bladder cancer), confirmed by a tissue sample, including certain variations of this cancer type - People who are considered suitable candidates for a major b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06186414 · Jiangsu Simcere Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to participate. - People aged 18 or older, of any gender. - People whose bladder cancer has been confirmed by laboratory testing to be a type called urothelial carcinoma, and whose cancer has not responded to BCG treatment (a common blad...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06187506 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed through a tissue biopsy with a type of bladder cancer called non-muscle-invasive urothelial cell carcinoma (a cancer that has not grown deep into the bladder wall) - People whose cancer is classified as "very high risk...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06190197 · University of Minnesota Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 15 October 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with muscle-invasive bladder cancer and are planning to have surgery to remove the bladder (called a radical cystectomy), with a plan to redirect urine through either a bag on the outside of the body or a new internal pouch made from bowel. - You are 18 ye...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06214572 · Tata Memorial Centre Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 21 July 2029
🇮🇳 IN

**Who might be able to join this trial:** - People who have been diagnosed with adenocarcinoma (a type of cancer) of the gallbladder, confirmed through a biopsy or tissue sample. This includes cancers starting at the neck of the gallbladder that may look similar to a nearby bile duct cancer. - People whose cancer has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06215976 · Cairo University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2024
🇪🇬 EG

**Who might be able to join this trial:** - Adults between 18 and 65 years old who do not have diabetes - People who have been diagnosed with bladder cancer and have not yet received any chemotherapy treatment - People whose kidneys are functioning well, based on a specific kidney function measurement being above a set...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06228066 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of bladder cancer called small cell carcinoma, or a similar high-grade neuroendocrine tumor in the urinary tract (such as in the kidney, ureter, or urethra — but not the prostate), confirmed by a tissue or cell sample. Mixed tumors that in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06241755 · Chengdu CoenBiotech Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People who have been newly and definitively diagnosed with medium- or high-risk bladder cancer that has not grown into the muscle wall (specific stages T1, Ta, or Tis), confirmed by tissue examination, and for whom BCG bladder...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06245603 · Istituto Oncologico Veneto IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You are generally able to carry out daily activities with little to no limitation from illness (confirm with trial site) - You have been diagnosed with bladder cancer that has not grown into the bladder muscle, whether this...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06246448 · Karolinska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇸🇪 SE

Who might be able to join this trial: - People who have had their gallbladder removed and imaging scans suggest, or have confirmed, a type of gallbladder cancer (stage T1b or higher) that was found unexpectedly, and where doctors have decided that further surgery to remove surrounding tissue is needed. - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06257017 · Yung NA Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2025
Hong Kong

**Who might be able to join this trial:** - People aged between 18 and 70 years old - People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, with a score of 0 or 1) - People who have had, or are scheduled to have, surgery to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06263153 · Yuanquan Yang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to sign a consent form agreeing to take part - People who weigh more than 30 kg - People whose tumour shows a specific protein marker (FGFR1, 2, or 3) at a high level, detected through a special tissue test called RNAScope - People who ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06269536 · Comenius University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2027
🇸🇰 SK

Who might be able to join this trial: - You must be older than 18 years of age. - You must have been diagnosed with a type of bladder cancer (urothelial carcinoma, including certain variations) confirmed by a biopsy showing the cancer has grown into the muscle of the bladder wall. - You must not have received any chemo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06281080 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
Hong Kong

Who might be able to join this trial: - People aged between 18 and 75 years - People with a body mass index (a measure of body weight relative to height) below 35 - People with a bladder tumour smaller than 3 cm that has not grown into the deep muscle wall of the bladder - People whose doctor has determined that an en-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06287541 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread into the bladder muscle) and have already had a first surgical procedure to remove the tumour, with a second similar procedure planned - People whose urine tes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06289270 · Theodor Bilharz Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇬 EG

Who might be able to join this trial: - Men aged 18 years or older. - People who have been diagnosed with bladder cancer using imaging tests such as ultrasound and/or CT scan, along with a urine test that looks for cancer cells. - People whose bladder cancer has been confirmed through a camera examination of the bladde...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06290687 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with bladder cancer (specifically urothelial carcinoma) confirmed by a tissue biopsy, at clinical stage T2-3N0M0. Certain subtypes of this cancer (micropapillary, glandular, squamous, and sarcomatoid) are also allowed. - People whose cancer is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06310759 · Tampere University Hospital Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇦 CA🇫🇮 FI🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - You are willing and able to give your consent to take part in the study - You have been scheduled for a cystoscopy (a procedure to look inside the bladder) to check whether or not you have bladder cancer Who may not be able to join: - You have previously been diagnosed with urot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06319820 · Janssen Research & Development, LLC Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 28 June 2028
🇦🇷 AR🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇫🇷 FR +12 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of early-stage bladder cancer (non-muscle-invasive bladder cancer at intermediate risk), confirmed by a tissue sample taken within the last 90 days, meeting certain grade and risk factor criteria (confirm with trial site for exact...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06335667 · University of California, Irvine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form. - A doctor at a UCI-affiliated clinic suspects you may have muscle-invasive bladder cancer based on what they saw during a routine camera examination of your bladder (cystoscopy). - You are generally able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06337942 · University of California, Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old. - You have a serious bladder condition that has caused ongoing infections, poor bladder function, or damage to your kidneys and urinary tract. - You have had bladder cancer (confined to the bladder, not spread) that required full removal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06341400 · Zhujiang Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate. - People aged 18 or older, of any gender. - People who are not able to receive cisplatin-based chemotherapy, or who have chosen not to receive it, for one of these reasons: kidney function below a certai...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06341478 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are already enrolled in, or eligible to join, one of three related clinical trials (NureCombo, SURE-01, or SURE-02), or you are being considered for surgery to remove your bladder as part of standard care - Your bladder cancer has been confirmed by a tissue sample (biopsy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06349642 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with, or are suspected of having, an advanced or metastatic cancer that includes certain types — such as non-small cell lung cancer, skin cancer (not uveal melanoma), esophageal, cervical, endometrial, liver, or colon cancer (a specific type only) — o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06364956 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, can give written consent, and are able to follow the study schedule and requirements. - People who are 18 years of age or older at the time of signing the consent form. - People who have been diagnosed with bladder cancer (uro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06373055 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2033
🇰🇷 KR

Who might be able to join this trial: - People who are suspected of having bladder cancer and are already scheduled to have a surgical procedure to remove a bladder tumour (called a transurethral resection). - People who agree to provide a biological sample (such as tissue or blood) for research purposes. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06373419 · Thunder Bay Regional Health Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇦 CA

Who might be able to join this trial: - People who are 18 years of age or older at the time of joining. - People who have had an outpatient camera examination of the bladder (cystoscopy) that showed signs suggesting a bladder tumor. Who may not be able to join: - People whose tumor a urologist has determined is not su...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06378242 · RemeGen Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to participate in the study. - You are a man or woman between 18 and 75 years old (inclusive). - You have been diagnosed with a type of bladder cancer (called non-muscle invasive bladder urothelial carcinom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06388720 · National Cancer Center, Korea Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇰🇷 KR

**Who might be able to join this trial:** - You are 20 years of age or older - You are willing and able to sign a written consent form to participate in the study - You have been diagnosed with high-risk non-muscle-invasive bladder cancer (a type of bladder cancer that has not grown deep into the bladder wall) that has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06389019 · Mingzhao Xiao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with bladder cancer and have had surgery, either to remove the bladder completely or to remove a tumour from inside the bladder - You had a CT scan with contrast dye taken less than two weeks before your surgery - Your full CT scan images and medical recor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06394570 · University of Texas Southwestern Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with bladder cancer (a specific type called urothelial carcinoma) at a certain stage (cT2-4a, meaning the cancer has grown into or through the bladder wall but has not spread to lymph nodes or other organs), who are planned to have their bladder surgically r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06394869 · Pacific Edge Limited Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been referred for evaluation of blood in your urine (either found under a microscope within the last 180 days, or detected by a urine dip test at your referral appointment and confirmed the same day) - You are physically able to provide a urine sample by urinating no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06396533 · Fox Chase Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a high-grade early-stage bladder tumor (called high grade T1) and, after being fully informed of your options, have chosen to have your bladder removed. - You have a non-invasive high-grade bladder tumor or pre-cancerous cells in the bladder lini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06414317 · Roswell Park Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

Who might be able to join this trial: **For Patients:** - You are 18 years of age or older - You have bladder cancer that has spread to other parts of the body or cannot be surgically removed - You are receiving or planning to receive drug treatment (such as chemotherapy or immunotherapy) for your bladder cancer at Ro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06417190 · Leslie Ballas Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with muscle-invasive bladder cancer (a type of bladder cancer that has grown into the muscle wall) with a specific tissue type, at a stage where it has not spread to distant parts of the body, confirmed by a bladder surgery procedure and body sc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06421142 · First Affiliated Hospital of Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇨🇳 CN

**Who might be able to join this trial:** *For the diagnostic part of the study:* - People who are suspected of having muscle-invasive bladder cancer (a type of bladder cancer that has grown into the muscle wall of the bladder) - People who have completed all three required scans: FAPI PET/MRI, FDG PET/MRI, and a stan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06427824 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - People who are able to give their own consent to participate - People aged 65 or older - People who have been diagnosed with bladder cancer (confirmed by tissue testing) and are scheduled to have their bladder surgically removed (called a radical cystectomy) along with a procedur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06434350 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with bladder cancer (a specific type called urothelial carcinoma, including mixed types) that has been confirmed by a pathology test, at certain stages of the disease - You are 18 years of age or older at the time of signing the consent form - You are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06441110 · Fujian Medical University Union Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and have signed a consent form agreeing to participate - People aged 18 to 75 years (any gender) with a life expectancy of at least 2 years - People who have been diagnosed through laboratory testing with a type of bladder cancer (non-musc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06470282 · University of California, San Francisco Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with muscle-invasive bladder cancer (stages cT2, T3, or T4a) confirmed by a biopsy, with a tissue sample available for testing. - People whose tumor contains urothelial cells (the most common bladder cancer cell type); mixed cell types are allo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06474338 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2033
🇨🇳 CN

Who might be able to join this trial: - People who have had a cystoscopy (a camera examination of the bladder) where the recorded video is available, and where one or more areas of concern in the bladder can be seen in that video. Who may not be able to join: - People whose cystoscopy video is too unclear or poor qual...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06488222 · University of Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - You have been diagnosed with a specific type of low-grade bladder cancer (called low-grade Ta urothelial carcinoma), which is either returning after a previous occurrence, a single tumor larger than 3 cm, or multiple tumors present at t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06493370 · University of Kansas Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form agreeing to take part - People who agree to take part in a related biological sample storage study (a separate biorepository study at the same institution) - People aged 18 or older, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06493552 · Vasgene Therapeutics, Inc Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2029
🇺🇸 US

**Who might be able to join this trial:** **General criteria for all participants:** - People who are willing and able to give their informed consent to take part. - Men and women aged 18 years or older. - People who are able to provide tumour tissue samples — either a cell block or at least 15 slides from a previous...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06503614 · John Sfakianos Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older at the time of giving consent. - People who are willing and able to follow the study schedule, attend all appointments, and sign a written consent form. - People whose general health and ability to carry out daily activities meets a specifi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06510374 · Ferring Pharmaceuticals Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇯🇵 JP🇵🇱 PL🇰🇷 KR🇪🇸 ES +1 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of bladder cancer called "intermediate risk non-muscle invasive bladder cancer," as defined by a major urology guideline from 2020 - You have had a surgical procedure to remove the bladder tumor (called TURBT, with or without chemo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06511141 · Axonics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time of joining the trial - You are able to fill out bladder diaries and patient questionnaires - Your main bladder problem is overactive bladder (OAB), meaning you experience sudden, strong urges to urinate, leaking urine due to those...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06511648 · Spanish Oncology Genito-Urinary Group Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇫🇷 FR🇮🇹 IT🇪🇸 ES🇬🇧 GB

Who might be able to join this trial: - People who have given written consent showing they understand the study and agree to take part. - People who have been diagnosed with muscle-invasive bladder cancer (a specific stage where the cancer has grown into the muscle wall but has not spread to distant parts of the body),...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06525571 · Johns Hopkins University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 4 January 2027
🇺🇸 US

Who might be able to join this trial: - People who are having a surgical procedure called TURBT to remove a bladder tumor that was found on imaging or during a camera examination of the bladder - People who are 18 years of age or older - People whose upper urinary tract (the kidneys and the tubes connecting them to the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06528990 · City of Hope Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 4 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with bladder cancer or colorectal (bowel) cancer - You are scheduled to have surgery that will include the creation of a stoma (an opening made in the abdomen to allow waste — either stool or urine — to leave the body through a pouch) - If you have bl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06529822 · Washington University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2030
🇺🇸 US

Who might be able to join this trial: This trial has four groups (called cohorts). The criteria below are organised by group. **Cohort 1 – Bladder or Upper Urinary Tract Cancer** - Adults aged 18 or older - General health that is reasonably well-maintained, as assessed by the treating doctor using a standard scale (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06537154 · Peter Black Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with bladder cancer that is mainly a type called urothelial carcinoma, and it has grown into the muscle wall of the bladder (confirmed by a tissue sample). - Your cancer is at a stage where it has not spread to dist...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06537960 · Hopital Foch Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇫🇷 FR

Who might be able to join this trial: - People aged 18 years or older - People who have been diagnosed with muscle-invasive bladder cancer (a specific stage of bladder cancer confirmed by tissue testing) found during a bladder examination procedure - People who are already scheduled to have a type of full-body scan cal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06545955 · Ferring Pharmaceuticals Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇵🇱 PL🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of bladder cancer called carcinoma in situ (CIS), with or without certain early-stage tumours (Ta or T1 high-grade disease), confirmed by medical records. For T1 disease, biopsy samples must show muscle fibres. - People who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06548529 · Peking University Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older and are generally able to carry out daily activities with little or no limitation - Your cancer cannot be removed by surgery, or it has spread to other parts of the body - Your tumor has tested positive, or possibly positive, for a protein called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06551233 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have already tried at least one type of treatment delivered directly into the bladder (such as BCG or gemcitabine) and it did not work - You are unwilling or unable to have BCG bladder treatment - You have had a standard surgical proced...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06567743 · CG Oncology, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of early-stage bladder cancer (called high-risk, high-grade non-muscle-invasive bladder cancer, or NMIBC) that has been confirmed by a tissue sample taken within the last 90 days. - Your cancer falls into one of three groups: (1)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06571708 · Columbia University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form for the trial. - People who are 18 years of age or older at the time of signing the consent form. - People with a life expectancy of more than 12 months. - People who are generally well enough to carry out daily...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06586255 · Abramson Cancer Center at Penn Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of bladder cancer called urothelial carcinoma (either pure or mixed with certain other subtypes). - You have had your bladder surgically removed (radical cystectomy) along with nearby lymph nodes within the past 48 weeks. - Your cancer was...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06595446 · Western University, Canada Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇦 CA

Who might be able to join this trial: - You are 18 years old or older and are having surgery to remove your bladder (called a radical cystectomy) along with the creation of an ileal conduit (a way of redirecting urine using a small piece of bowel, which drains into a bag on the outside of the body) for bladder cancer -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06630416 · Northwestern University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 May 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have metastatic bladder cancer (Arm A) or another advanced solid tumour cancer (Arm B), AND whose tumour has a specific gene or protein change in MLL4 (KMT2D gene), UTX (KDM6A gene), or MTAP, detected by genetic sequenc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06637423 · Merck Sharp & Dohme LLC Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 14 March 2029
🇨🇦 CA🇫🇷 FR🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People who have recurring low-grade bladder cancer (a type that has not spread into the bladder muscle) that has come back after previous treatment - People whose bladder tumor was visible during a camera examination of the bladder (cystoscopy) within the 12 weeks before starting...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06644755 · Daiichi Sankyo Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 30 November 2028
🇧🇪 BE🇫🇷 FR🇳🇱 NL🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with one of the following cancers (confirmed by lab testing of tissue or cells): advanced or spread synovial sarcoma (SS), advanced or spread myxoid round cell liposarcoma (MRCLS), non-small cell lung cancer that has...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06651697 · University of California, San Diego Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - People aged 18 years or older - People who have signed and dated a consent form agreeing to take part in the study - People who are willing and available to follow all study procedures for the full duration of the trial - People whose doctors have determined them suitable to rece...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06662071 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (any gender) - You have been diagnosed with intermediate-risk or high-risk bladder cancer that has not grown into the bladder muscle, and your doctor has recommended bladder wash-out (instillation) treatment - You have not previously had b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06663137 · Relmada Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇮🇱 IL

**Who might be able to join this trial:** - People aged 18 to 80 years old. - People who are able to give informed consent (agree to participate after being fully informed about the study). - People who have been diagnosed with high-grade non-muscle-invasive bladder cancer (a type of bladder cancer that has not grown...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06679920 · Amsterdam UMC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇳🇱 NL

Who might be able to join this trial: - You must be over 18 years old. - You must have at least one suspected bladder tumour that was seen during a bladder camera examination (cystoscopy). - Your bladder must be able to be reached and examined with a camera (cystoscopy). - You must be healthy enough to undergo a proced...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06682728 · University of California, Irvine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People who are well enough to carry out daily activities with minimal to no limitation (as assessed using a standard medical scoring tool called the ECOG scale, with a score of 0, 1, or 2). -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06689176 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to sign and date a consent form agreeing to take part in the study. - People who are available for the full length of the study and willing to follow all study procedures, including doing twice-daily irrigation (rinsing) of their neobladder or ileal con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06696742 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2029
🇨🇳 CN

**Who might be able to join this trial:** - (For pre-surgery treatment) You have bladder cancer at a certain stage (T2 to T4a) that has not spread to nearby lymph nodes or other parts of the body - (For post-surgery treatment) After surgery, your cancer was found to have reached a more advanced stage (T3 or T4) and/or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06696794 · Shaogang Wang Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form and are able to follow all steps of the trial from start to finish. - You are between 18 and 75 years old (any gender). - Your general health and ability to carry out daily activities is rated as good or fully active (confirm with trial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06703476 · Memorial Sloan Kettering Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2028
🇺🇸 US

Who might be able to join this trial: - People aged 21 years or older who are scheduled to have a radical cystectomy (surgery to remove the bladder) as a treatment for bladder cancer, performed by a participating surgeon at Memorial Sloan Kettering (MSK) Who may not be able to join: - For the part of the trial involvi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06704191 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - (Phase 1b only) People of any gender who have been diagnosed with non-muscle invasive bladder cancer (an early stage of bladder cancer that has not spread into the bladder muscle, classified as stage Ta, Tis, or T1) and are currently in the early treatment phase using one of thes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06709196 · Rigshospitalet, Denmark Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2027
🇩🇰 DK

Who might be able to join this trial: - People who are 18 years of age or older at the time of surgery - People who are able to understand and sign a consent form agreeing to take part - People who are having their bladder removed, whether for a cancerous or non-cancerous reason - People whose surgical plan includes a...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06712420 · Rajiv Gandhi Cancer Institute & Research Center, India Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2028
🇮🇳 IN

**Who might be able to join this trial:** - People with a performance status rated 0, 1, or 2 on the ECOG scale, meaning they are reasonably active and able to carry out daily activities to some degree (confirm with trial site) - People with gallbladder cancer (GBC) that has grown into nearby tissues or spread to near...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06719232 · Jahn Ferenc South Pest Teaching Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇭🇺 HU

**Who might be able to join this trial:** - Adults between 18 and 80 years old (both men and women) - People whose doctor has decided they need a treatment where medicine is put directly into the bladder for one of the following reasons: a painful bladder condition (interstitial cystitis/bladder pain syndrome), frequen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06721260 · University of Kansas Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People who have a confirmed cancer diagnosis - People who are scheduled to receive platinum-based chemotherapy followed by surgery to remove the bladder - People whose kidneys and heart are functioning well enough to safely receive platinum-based chemotherapy Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06729346 · Armed Forces Institute of Urology, Rawalpindi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2025
🇵🇰 PK

Who might be able to join this trial: - Any patient who has a bladder tumor Who may not be able to join: - Anyone who is younger than 18 years old - Anyone who is older than 75 years old Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06732531 · Zhuhai Beihai Biotech Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been fully informed about the study and have voluntarily agreed in writing to take part and follow the study process. - Adults aged 18 or older at the time of signing consent, of any gender. - People who had a bladder tumour removal procedure (called TURBT) comple...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06733363 · Roswell Park Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 January 2028
🇺🇸 US

**Who might be able to join this trial:** - You speak English - You have been diagnosed with early-stage bladder cancer (stage Tis, Ta, or T1) - You are 18 years old or older (there is no upper age limit) - You live in New York State - Your cancer was diagnosed through normal medical channels, not only through a lab re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06735287 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a large bladder cancer that has not grown into the muscle wall of the bladder (the tumor is 5 cm or larger, there are 3 or fewer tumors, and imaging or biopsy results meet specific criteria). - Your heart, bone marrow, liver, and kidneys are work...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06763354 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study - You are between 19 and 84 years old - You have been diagnosed with a bladder tumour through a camera examination of the bladder (a procedure called a cystoscopy), and you do not necessari...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06770582 · National Cancer Institute (NCI) Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 February 2032
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of early-stage bladder cancer (called T1 high-grade non-muscle invasive urothelial carcinoma) confirmed by a tissue biopsy, with no signs of cancer spread to nearby lymph nodes or other parts of the body on scans. - Your doctors w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06775977 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with primary bladder cancer, confirmed through a lab test of tissue or cell samples - You have not had any surgery, chemotherapy, immunotherapy, or other treatments before the special ultrasound scan (CEUS) used in this...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06781879 · Jakob Kristian Jakobsen Phase 4 · 4 countries Recruiting
Recruiting Phase 4 Est. completion 1 February 2029
🇩🇰 DK Iceland🇳🇴 NO🇸🇪 SE

Who might be able to join this trial: - People whose bladder cancer has come back after a previous low-grade, non-invasive bladder tumour (called Ta low-grade) - People whose tumour is smaller than 2 cm across - People whose urine test (cytology) did not find any cancer cells — this test is optional - People who are 18...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06787053 · University of Manchester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2028
🇬🇧 GB

**Who might be able to join this trial:** - You are older than 18 years of age. - You have bladder, cervix, or prostate cancer and are receiving radiotherapy at The Christie NHS Foundation Trust. - You are medically suitable to have an MRI scan. - You are able to give your informed consent to take part in the study. *...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06800963 · ImmunityBio, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a type of bladder cancer called non-muscle invasive urothelial carcinoma (a cancer that has not grown deep into the bladder wall), confirmed by a tissue sample, and you have never received BCG treatment for it -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06809140 · Matthew Galsky Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with muscle-invasive bladder cancer (a specific type called urothelial cancer) that has not spread to lymph nodes or other parts of the body (stage T2-3N0M0), confirmed by a tissue sample; tumors with some mixed cell...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06818136 · Nucleix Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who are 45 years of age or older - People who are willing and able to sign a consent form and follow the study procedures - People who have had blood in their urine (either visible or detected by testing) in the 6 months before joining the study - People who are alread...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06820255 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 7 January 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a consent form before any study-related procedures begin. - People aged 18 or older. - People who have a confirmed diagnosis of urothelial cancer (a type of cancer that affects the lining of the bladder and...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06822010 · Rutgers, The State University of New Jersey Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have signed a consent form and are willing and able to follow all study requirements - People who are at least 18 years old - People who have been diagnosed with high-grade, non-invasive upper urinary tract cancer (in the kidney collecting system or ureter), eithe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06878027 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 February 2026
🇮🇹 IT

**Who might be able to join this trial:** *For patients with bladder cancer:* - You are 18 years of age or older - You have a confirmed diagnosis of bladder cancer (either the type that has grown into the muscle wall or the type that has not) - You are generally active and able to carry out daily activities with littl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06879145 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2031
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years of age or older (any gender can apply) - You must be willing to take part and have signed a consent form agreeing to join the study - Your general health and ability to carry out daily activities must be rated as very good or fully active (confirm with trial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06889623 · Changhai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with high-risk non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread deep into the bladder wall), confirmed by a camera examination of the bladder, including specific types such as high-grade T1, recurring high-grade Ta, c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06891209 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - You are currently living after having had a partial bladder removal surgery, and are already in a specific Mayo Urology patient registry, or you are about to undergo a full or partial bladder removal surgery. - You are a patient who had a full bladder removal surgery, being match...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06892860 · Queen Mary University of London Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇫🇷 FR🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate. - People who are able to follow the study requirements, including regularly completing quality-of-life questionnaires. - People aged 18 or older. - People who have been diagnosed through a tissue biopsy...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06896162 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are aged 18 or older at the time of signing consent forms. - People who are willing and able to follow the study procedures, as determined by the trial doctor. - People who have been diagnosed with Stage IV (advanced, spread) cancer of one of these types: non-smal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06916494 · First Affiliated Hospital of Chongqing Medical University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with muscle-invasive bladder cancer (a type of bladder cancer that has grown into the muscle wall) at a specific stage that has not spread to lymph nodes or other parts of the body - People whose cancer did not respond after 2 rounds of a standard chemotherap...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06919965 · Janssen Research & Development, LLC Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 6 April 2028
🇦🇷 AR🇧🇪 BE🇧🇷 BR🇨🇳 CN🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇱 IL +7 more

**Who might be able to join this trial:** - People who have been diagnosed by a pathologist with a specific type of early-stage bladder cancer called high-grade non-muscle-invasive bladder cancer (HR-NMIBC) that is papillary (wart-like growths) only, with no flat lesions (called CIS). Certain mixed tumour types may be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06929286 · Memorial Sloan Kettering Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 21 years of age or older - People who are being treated for a specific type of bladder cancer called high-grade non-muscle-invasive bladder cancer (a cancer that stays in the inner lining of the bladder) by one of the urologists involved in this trial - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06971614 · ImmVira Pharma Co. Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form, of any gender - People who have been diagnosed with a specific type of early-stage bladder cancer (non-muscle-invasive bladder cancer, including types known as Ta, T1, and/or CIS), confirmed by tissue testing -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06972615 · BLATAM Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇦🇷 AR

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the trial. - You are 18 years of age or older at the time of signing the consent form. - You have been diagnosed with a specific type of bladder cancer (called transitional cell carcinoma) that is high-...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06972771 · Yunnan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 80 years old - You have a suspected bladder cancer that has not spread into the muscle wall, and you are already scheduled to have surgery for it - You are considered healthy enough to safely have an operation - You are able to understand the study informat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06977906 · First Affiliated Hospital of Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with high-risk prostate cancer confirmed by a biopsy and at least one of the following: a PSA level above 20 ng/mL, a Gleason score of 8 or higher, or a specific stage of tumor spread (confirm with trial site), and you have had or are planned to have r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06986304 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People who are over 18 years of age. - People who have been diagnosed with bladder cancer (confirmed by tissue testing) for which their treating doctor has recommended surgical removal of the bladder — for example, muscle-invasive bladder cancer, or high-risk non-muscle-invasive...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06988696 · Istanbul University - Cerrahpasa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - The surgery is expected to last between 2 and 4 hours - The person is able to read, write, understand, and communicate in Turkish - Participation is fully voluntary - Intensive care is not needed before or after the surgery - No diagnosis of a condition that affects memory o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06991868 · Peking University First Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇳 CN

**Who might be able to join this trial:** This trial has four separate groups (called cohorts). Each group has its own criteria. --- **Cohort I – Upper urinary tract cancer (kidney pelvis or ureter) after major surgery:** Who might be able to join this trial: - People aged 18 or older who are able to legally consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06992986 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 July 2025
🇮🇹 IT

**Who might be able to join this trial:** **If you have bladder cancer:** - You have been diagnosed with bladder cancer - Your urine test shows no signs of infection (negative urine culture) - Your cancer has been confirmed by tissue testing as a specific type called urothelial carcinoma - You are scheduled to have yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07000084 · Alliance for Clinical Trials in Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 5 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of bladder cancer called urothelial carcinoma, confirmed by a tissue sample taken within the last 120 days, and classified as high grade Ta, high grade T1, or carcinoma in situ (CIS — a very early stage confined to the blad...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07019220 · Ekaterina Laukhtina Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇦🇹 AT

**Who might be able to join this trial:** - Adults aged 18 or older who have given written consent to participate - People who have been diagnosed with a specific low-grade, early-stage bladder cancer (called TaLG bladder cancer), either as a first-time diagnosis or as a return of a previously treated cancer, confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07020117 · Aktis Oncology, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Your cancer has been confirmed by a tissue or cell sample (biopsy) and has either spread to other parts of the body or is at an advanced stage that cannot be removed with surgery - A CT scan has shown at least one tumor that can be measured according to standard guidelines -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07025174 · First Affiliated Hospital of Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are between 18 and 75 years old at the time of joining the trial - People who have been diagnosed (confirmed by laboratory testing of tissue or cell samples) with advanced or spread-out bile duct or gallbladder cancer (specifically intrahepatic cholangiocarcinoma, extr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07029256 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2030
🇺🇸 US

Who might be able to join this trial: - People who are scheduled to have their bladder surgically removed due to confirmed or suspected bladder cancer - People who have had imaging scans of their abdomen taken before the surgery Who may not be able to join: - People who have previously had part of their bladder remove...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07030257 · Tasca Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People whose cancer can be measured or tracked by researchers to see if it changes over time - People for whom existing standard cancer treatments are not suitable or are no longer an option - People who have a tumor tissue sample available for lab testing, or who are willin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07037589 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇸🇪 SE

Who might be able to join this trial: - Women aged 50 or older - People who have visible blood in their urine (urine that appears red, pink, or brown) - People who are attending a specialist clinic specifically for the assessment of visible blood in their urine - People who are able to understand and agree to participa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07038928 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇷🇺 RU

**Who might be able to join this trial:** - People aged 18 or older - People who have signed a consent form, including agreeing to have a stored tumour tissue sample tested - People who have a confirmed diagnosis of urothelial bladder cancer, at one of three stages: non-muscle-invasive (NMIBC), muscle-invasive (MIBC),...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07048496 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 August 2026
🇺🇸 US

**Who might be able to join this trial:** **Group 1 – Patients:** - You are 18 years old or older - You have had internal bladder treatment (treatment placed directly into the bladder) for early-stage bladder cancer that does not go deep into the bladder wall, and finished that treatment within the past year **Group...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07051083 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Imaging tests (such as ultrasound, CT, or MRI) have found a growth in your bladder that may be bladder cancer - Your bladder can be fully filled with fluid for the scan, and you have no known allergic reactions to ultrasound contrast agents (a special dye used during scans) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07061964 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with muscle-invasive bladder cancer (a specific type and stage) confirmed by tissue testing within the past 180 days before starting pre-surgery treatment - People who had a CT scan, MRI, or PET scan of the chest, abdomen, and pelvis within 60...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07067749 · University of Rome Tor Vergata Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 August 2028
🇮🇹 IT

Who might be able to join this trial: - People for whom doctors suspect bladder cancer that has grown into the muscle wall, based on a camera examination of the bladder (cystoscopy) and imaging done before that procedure. Who may not be able to join: - People whose other health conditions mean they are not expected to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07073703 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with bladder or kidney cancer - People whose treatment plan includes surgery (not yet completed) - People who do not have severe cognitive difficulties that would prevent them from understanding the study requirements - People who are covered by a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07080333 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years old - People who are male - People who are scheduled for their first surgical removal of a suspected bladder tumour (a procedure called TURBT), based on signs such as blood visible in the urine, abnormal urine test results, bladder examination fin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07088536 · Jagiellonian University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇵🇱 PL

**Who might be able to join this trial:** - Adults aged 18 or older who are admitted to the Department of Urology and Oncological Urology at the University Hospital in Kraków during the 6-month study period. - People who are currently employed at the time of entering the study (for the follow-up part of the trial). - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07097142 · NRG Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with urothelial carcinoma (a type of bladder cancer) confirmed by laboratory testing, at a specific stage (cT2-T3, N0M0 — meaning the tumour has grown into the bladder wall but has not spread to lymph nodes or other parts of the body) before be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07111364 · Peking University First Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older and a possible bladder growth has been spotted on an ultrasound scan of your abdomen - You are already planned to have surgery to treat a bladder tumour **Who may not be able to join:** - You are older than 85 years of age - You are unable to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07119996 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part, can sign a consent form, and are able to follow the study schedule and requirements. - You are 18 years old or older at the time of signing the consent form. - You are reasonably active and able to care for yourself, with little or no limitation...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07122414 · Suzhou Forlong Biotechnology Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a specific type of bladder cancer (called high-grade transitional cell carcinoma) that has not grown into the bladder muscle, confirmed by a tissue sample - Your bladder cancer has not responded to BCG treatment...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07129993 · Daiichi Sankyo Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2029
🇦🇹 AT🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years old or older (or meet the legal age of consent in your country) at the time you sign the consent form. - You must have been diagnosed (confirmed by a lab test of tissue or cells) with a type of bladder or urinary tract cancer called urothelial carcinoma...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07130578 · Tianjin Medical University Second Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older, either male or female - You have been diagnosed with a bladder tumor that has **not** grown into the bladder muscle, and there is no sign it has spread to other parts of the body, confirmed by a tissue sample analysis - Your bladder tumor is...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07140315 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to sign a consent form agreeing to take part in the trial. - You must be 18 years of age or older and able to understand and agree to the consent process. - You must have been diagnosed with a specific type of lung cancer (non-small cell lung can...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07144319 · Photocure Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇳🇴 NO🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older - You must be willing and able to sign a consent form that has been approved by an ethics review board - You must have been prescribed a medication called Hexvix or Cysview in the standard, approved way - Your doctor must have already planned to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07165236 · Osijek University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇭🇷 HR

**Who might be able to join this trial:** - Adults between 18 and 80 years of age - People scheduled for a planned (non-emergency) surgical procedure to treat bladder cancer (a procedure called TUR, which removes tumour tissue from the bladder) - People who are able to communicate - People who are able to sign a consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07180212 · Tianjin Medical University Second Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 years or older, of any gender. - People who have been diagnosed within the past 2 years with a specific type of bladder cancer called high-risk or very high-risk non-muscle-invasive urothelial carcinoma (a cancer that has not grown into the deeper muscle layer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07187063 · Lahey Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with high-risk bladder cancer, as classified by the American Urological Association (AUA) - People who have already completed an initial course (called "induction") of either BCG therapy or a combination of gemcitabine and docetaxel delivered direct...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07187635 · Tianjin Medical University Second Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older, of any gender. - People who have been diagnosed through laboratory testing with a type of bladder tumor that has not grown into the muscle wall of the bladder and has not spread to other parts of the body. - People whose bladder tumor has been confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07202819 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 May 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with a specific stage of bladder cancer (called cT2 urothelial carcinoma) based on standard cancer staging guidelines, and who have given written agreement to take part in the study and follow its requirements. Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07202845 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with a type of bladder cancer called urothelial carcinoma, at a stage classified as cT2 to cT4, and who have given written agreement to take part in the study and follow its requirements. - People whose treatment plan includes receiving a chemothera...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07204132 · Changhai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 85 years old (any gender) - You have been diagnosed with bladder tumors and confirmed through a biopsy or bladder surgery (TURBT) to have high-risk, early-stage bladder cancer that has not grown into the bladder muscle — this includes tumors at T1 stag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07206225 · Pfizer Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 29 January 2030
🇫🇷 FR🇮🇱 IL🇰🇷 KR🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older (or meet the minimum age required by local rules) - People who have been diagnosed with a specific type of early-stage bladder cancer — called high-risk, non-muscle invasive urothelial carcinoma — confirmed by a tissue sample, includin...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07207824 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2030
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older. - People who have been diagnosed through a tissue biopsy with high-risk bladder cancer that has not grown into the muscle wall, where the main cancer cell type is urothelial carcinoma (making up more than half of the sample). - People whose bladder tumour...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07217171 · EvolveImmune United, Inc Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 29 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have locally advanced or metastatic cancer of one of these types: bladder cancer, squamous cell carcinoma of the lung, esophagus, skin, or an anogenital (anal or genital area) squamous cell carcinoma. - People whose cancer has continued to grow or spread during or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07222488 · Merck Sharp & Dohme LLC Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 28 February 2029
🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇬🇷 GR🇮🇱 IL🇮🇹 IT🇳🇱 NL +4 more

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of early-stage bladder cancer (called carcinoma in situ, with or without high-risk non-muscle invasive bladder cancer), confirmed by a laboratory test on tissue samples. - People whose most recent bladder tumour removal sur...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07225127 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 years or older - People who currently have a confirmed diagnosis of high-grade non-muscle-invasive bladder cancer (a type of bladder cancer that has not grown into the bladder muscle), at a stage classified as Tis, Ta, or T1, based on laboratory analysis of ti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07225205 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with a type of bladder cancer called urothelial carcinoma, confirmed by a pathology test, including types that have or have not grown into the bladder muscle, as well as certain variant forms - People who have decided...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07227077 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - You are 65 years old or older - You have been diagnosed and treated for bladder, breast, cervical, colorectal, endometrial, lung, or prostate cancer - You can speak and read English fluently - You have access to a smartphone - You are able to understand and willing to sign a cons...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07232602 · Merck Sharp & Dohme LLC Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 8 July 2031
🇨🇱 CL🇫🇷 FR🇮🇱 IL🇳🇱 NL🇰🇷 KR🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with bladder or urinary tract cancer (called urothelial carcinoma) that has either spread to nearby areas and cannot be removed by surgery, or has spread to other parts of the body - You are able to provide a tumor tissue sample, either one taken rece...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07234968 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to sign a consent form agreeing to take part in the study - People who are able to follow all study procedures and commit to participating for the full duration of the study - People who are between 18 and 85 years old (male or female) - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07278479 · Molecular Partners AG Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed (confirmed by tissue or cell testing) with advanced small cell lung cancer (SCLC) at any stage, whose cancer has come back or continued to grow after at least two previous treatments including platinum-based chemotherapy an...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07283835 · Lepu Biopharma Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You must be 18 years of age or older at the time you sign the consent form - You must have been diagnosed with a specific type of bladder cancer (non-muscle-invasive bladder cancer with carcinoma in situ) that has stopped responding to a common bladder cancer treatment calle...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07285044 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 18 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of giving consent - People who have been diagnosed with cancer (confirmed by lab testing of tissue), or in the case of liver cancer (hepatocellular carcinoma), by imaging scans alone - People whose cancer type is one of those listed as eli...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07296705 · Fujian Medical University Union Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part, can give written consent, and are able to follow the study schedule and requirements. - People aged 18 to 85 years old at the time of signing the consent form. - People who have bladder cancer that remains after a surgical procedure to re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07302230 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have previously been diagnosed with early-stage bladder cancer (cancer that has not spread into the bladder muscle) and are currently being monitored or receiving treatment directly into the bladder - You have been assessed as not getting e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07307456 · Changhai Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 8 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old. - People who have been diagnosed with high-risk or very high-risk bladder cancer that has not grown into the muscle wall of the bladder, confirmed by a tissue sample taken during a surgical procedure or biopsy. - People who have not p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07309445 · Janssen Research & Development, LLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread into the bladder muscle), confirmed through a surgical or biopsy procedure. - People who have already started their first dose of a treatment called TAR-200 in a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07318051 · Natera, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with a primary (original, not spread-from-elsewhere) solid tumor cancer that has not yet been treated, in one of these cancer types: breast, lung, muscle-invasive bladder, rectal, pancreatic, ovarian, gastroesophage...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07319923 · Peking University First Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - You are a man living in the community who is 50 years old or older - Your general health is reasonably good and doctors expect you to live for more than 10 years - You are a permanent resident of Beijing and are willing to take part in screening, complete any required tests and q...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07322263 · Michael A. O'Donnell Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2033
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with bladder cancer (specifically urothelial carcinoma) confirmed by a tissue sample, with no involvement of the upper urinary tract or the part of the urethra that passes through the prostate. - People whose bladder cancer is either carcinoma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07337525 · Pilatus Biosciences Inc Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to give written consent to participate - People with an advanced solid tumour (not originating in the brain or spinal cord) that has been confirmed through a tissue or cell sample - People whose cancer has at least one area that can be mea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07339761 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇩🇰 DK

**Who might be able to join this trial:** *Study 1a:* - People who were diagnosed with bladder cancer that had not spread into the muscle wall, and who were treated with surgery to remove the tumour from inside the bladder (about 12 months ago) - People who were diagnosed with bladder cancer that had not spread into t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07359235 · Tongji Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with bladder cancer through laboratory testing, specifically high-risk non-muscle-invasive bladder cancer (cancer that has not spread into the bladder muscle) with certain features such as high-grade tumors, cancer in the lining only (carcinoma...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07379255 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 80 years, of any gender - People who have had surgery to remove the bladder (radical cystectomy), where tissue from the removed bladder will be used to grow laboratory cell cultures called organoids - People whose bladder cancer has been found to have s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07379268 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 80 years, of any gender - People with bladder cancer who have a tumor biopsy sample taken before starting ADC treatment, which will be used for a laboratory process called organoid culture - People with bladder cancer that cannot be surgically removed and has ei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07379281 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (any gender) - You have been diagnosed with muscle-invasive bladder cancer (a stage where the cancer has grown into the muscle wall of the bladder) that has not spread to distant parts of the body, and your doctor has recommended chemother...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07413523 · Istituto Clinico Humanitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2030
🇮🇹 IT

**Who might be able to join this trial:** - You must be over 18 years old - You must be well enough to carry out some daily activities — your overall health and ability to function must meet a certain standard set by the World Health Organization (confirm with trial site) - Your cancer must have been confirmed through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07420517 · Paul Toren Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 2 April 2030
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a specific type of low-grade bladder cancer (called low-grade non-muscle invasive urothelial carcinoma), confirmed through a laboratory tissue test. People with a mix of low- and high-grade bladder cancer may also...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07424287 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2030
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older (any gender) - People whose general health and ability to carry out daily activities meets a certain threshold, as measured by a standard medical scale called the ECOG scale (score of 2 or lower) - People who have been diagnosed through tissue testing...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07424560 · Zhilong Dong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with bladder cancer (confirmed by a lab test looking at tissue under a microscope), at any stage. - There is enough tumor tissue from your biopsy or surgery that has been stored frozen, so it can be used for genetic testing. - You are 18 years old or older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07441499 · Tianjin Medical University Second Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People with a suspected or confirmed diagnosis of urothelial carcinoma (a type of cancer that affects the lining of the bladder and urinary tract) Who may not be able to join: - People who have had, or currently have, another type of cancer in addition to urothelial carcinoma I...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07474519 · Ohio State University Comprehensive Cancer Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People diagnosed with intermediate or high risk non-muscle-invasive bladder cancer who have been recommended for a course of BCG treatment given directly into the bladder - People who have not yet started their BCG treatment course - People who are able to lie flat on their back...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07475403 · Tianjin Medical University Second Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older - People with a bladder cancer diagnosis confirmed by laboratory testing, specifically a type called urothelial carcinoma that has not grown into the bladder muscle, and classified as "very high risk" based on 2025 European urology guidelines - People whos...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07475806 · Astellas Pharma Global Development, Inc. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇯🇵 JP🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - Your bladder cancer has been confirmed by a tissue test (biopsy) and is at a specific stage — muscle-invasive, meaning it has grown into the bladder muscle, and has not spread widely to distant parts of the body (confirm specific staging details with trial site). - Your canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07480356 · Protara Therapeutics Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2028
🇺🇦 UA🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have voluntarily signed a written consent form after having the study explained to them - People with a confirmed diagnosis (verified by a central laboratory) of high-grade non-muscle...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07492628 · Beijing Biotech Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 14 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years at the time of consenting to join the trial - People with a laboratory-confirmed diagnosis of urothelial carcinoma (a type of cancer affecting the bladder, ureter, kidney pelvis, or urethra) that cannot be surgically removed or has spread to other...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07494864 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇨🇭 CH

**Who might be able to join this trial:** - You are a woman or man aged 18 or older - You are able to give your consent to take part in the study - You are willing to follow the study rules and schedule for the full length of the trial - You are willing to have a thin tube (catheter) briefly inserted to collect a urin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07495072 · BLAD-HYA Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇰🇷 KR

Who might be able to join this trial: - Adults aged 19 years or older - People who have been diagnosed with bladder cancer that has not grown into the muscle wall of the bladder, confirmed through a tissue sample examination - People whose doctors have identified them as suitable candidates for a treatment placed direc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07514143 · Nucleix Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 22 years of age or older - You are willing and able to sign a consent form to participate in the study - You are scheduled to have one of the following procedures within the next 60 days: a surgical procedure to remove or examine a bladder tumor (TURBT), a camera exam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07514897 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with bladder cancer, or your doctor suspects you may have it - You have a non-cancerous urological condition, such as kidney stones, bladder stones, bladder inflammation (cystitis), or a narrowed ureter - You are willing to allow your urine and tissue...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07524426 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2032
🇸🇪 SE

Who might be able to join this trial: - People who are willing and able to give consent to take part, both verbally and in writing - People who have been diagnosed with muscle-invasive bladder cancer that has been confirmed through laboratory testing of tissue, and whose cancer includes a specific cell type called urot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07545694 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older - People who have been diagnosed with bladder cancer at any stage, and are either having surgery straight away or have been receiving treatment before surgery (for more than 6 weeks), with surgery planned as the main treatment - People who have agreed to t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07566156 · Astellas Pharma Global Development, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with muscle-invasive bladder cancer (a cancer that has grown into the muscle wall of the bladder), confirmed by a tissue biopsy, with the cancer mainly being of the urothelial type (the most common bladder cancer cell type), and staged at a spe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07589413 · Zhiping Wang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People who have suspected or confirmed bladder cancer of a specific type called urothelial carcinoma - People who are already scheduled to have a surgical procedure called TURBT (a procedure to remove bladder tumours) - People for whom enough...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07594964 · Shenzhen Xinhe Biomedical Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 October 2029
🇨🇳 CN

Who might be able to join this trial: - You are willing and able to sign and date a consent form to participate in the study - You are between 18 and 70 years old (male or female) - You have been diagnosed with a high-risk solid tumour that may come back after having surgery to remove it — this mainly includes pancreat...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07602010 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇳🇴 NO

Who might be able to join this trial: - People aged 18 years or older - People who have been newly diagnosed with bladder cancer during a cystoscopy (a procedure where a camera is used to look inside the bladder) - People who have a planned surgery to remove bladder tissue (TURBT) or the whole bladder (cystectomy) sche...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07607990 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old (inclusive) - People whose overall health before surgery falls within a certain accepted range, as assessed by an anaesthesiologist (known as ASA Class I–III — confirm with trial site if unsure what this means) - People scheduled for a planned (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07614594 · Henan Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years old or older. - You have blood in your urine, either visible to the eye or detected by a test. - A scan (ultrasound, CT, or MRI) has shown a growth or abnormality in your kidney, ureter (the tube connecting the kidney to the bladder), or bladder. - You are al...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646145 · Shanxi Province Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a written consent form agreeing to participate - You are 18 years of age or older (any gender) - You have already had a surgical procedure called TURBT (removal of bladder tumors) before joining, and no obvious remaining tumor was...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07647289 · Peking University Third Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and able to sign a consent form agreeing to participate. - You are between 18 and 80 years old at the time of signing the consent form. - You are generally active and able to care for yourself, with only mild limitations on physical activity (con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07673016 · Convergent Genomics, Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2034
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** **Group 1 – Bladder Cancer and/or Upper Tract Urothelial Cell Carcinoma (UCC):** - People aged 18 or older who are scheduled for a surgical procedure to remove or examine a bladder tumor or take a tissue sample from the urinary tract - People who previously had urothelial cell...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07678489 · Sami-Ramzi Leyh-Bannurah Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇩🇪 DE

**Who might be able to join this trial:** - People whose doctors estimate they have a life expectancy of 10 years or more based on their biological age - People who have not previously had any prostate treatments, such as laser surgery, TURP (a procedure to clear a blocked urethra), or focal therapy (targeted tumour t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07717242 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, can give written consent, and are able to follow the study schedule and requirements. - People who are 18 years of age or older at the time of signing the consent form. - People who have been diagnosed through tissue testing a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07726602 · OHSU Knight Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of giving consent - People of any gender, gender identity, race, or ethnicity - People with a new diagnosis of muscle-invasive bladder cancer (a type of cancer that has grown into the muscle wall of the bladder), confirmed by laboratory te...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03621982 · ADC Therapeutics S.A. Phase 1 · 3 countries Terminated
Terminated Phase 1 Est. completion 14 December 2022
🇧🇪 BE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender, who are willing and able to provide written consent before any procedures begin. - People who have been diagnosed with a locally advanced or metastatic solid tumour cancer — including colorectal, head and neck, non-small cell lung, gas...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Bladder Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Bladder cancer support in Australia is spread across a few organisations, each with a slightly different focus: the Bladder Cancer Australia Charity Foundation, BEAT Bladder Cancer Australia, and Bladder Cancer Awareness Australia. It's worth comparing them to see which suits you.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.